Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 81Neoplasm Metastasis 69Colorectal Neoplasms 68Leukemia, Myeloid, Acute 66Neoplasms 64Breast Neoplasms 48Prostatic Neoplasms 46Multiple Myeloma 44Ovarian Neoplasms 39Squamous Cell Carcinoma of Head and Neck 38Pancreatic Neoplasms 38Recurrence 35Melanoma 34Lymphoma, Non-Hodgkin 30Lung Neoplasms 30Myelodysplastic Syndromes 29Glioblastoma 28Triple Negative Breast Neoplasms 27Advanced Solid Tumors 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Endometrial Neoplasms 25Carcinoma, Renal Cell 24Small Cell Lung Carcinoma 23Stomach Neoplasms 20Lymphoma, B-Cell 20Carcinoma, Hepatocellular 20Brain Neoplasms 20Sarcoma 19Lymphoma, Large B-Cell, Diffuse 16Head and Neck Neoplasms 16

Interventions

pembrolizumab 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Lymphoid × 30 days × Clear all
NCT03219450 2026-05-28

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Dana-Farber Cancer Institute

Phase 1 Recruiting
15 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Lymphoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡